Genotype-phenotype correlation in neurofibromatosis type-1: NF1 whole gene deletions lead to high tumor-burden and increased tumor-growth.


Journal

PLoS genetics
ISSN: 1553-7404
Titre abrégé: PLoS Genet
Pays: United States
ID NLM: 101239074

Informations de publication

Date de publication:
05 2021
Historique:
received: 20 12 2020
accepted: 29 03 2021
entrez: 5 5 2021
pubmed: 6 5 2021
medline: 23 9 2021
Statut: epublish

Résumé

Neurofibromatosis type-1 (NF1) patients suffer from cutaneous and subcutaneous neurofibromas (CNF) and large plexiform neurofibromas (PNF). Whole gene deletions of the NF1 gene can cause a more severe phenotype compared to smaller intragenic changes. Two distinct groups of NF1 whole gene deletions are type-1 deletions and atypical deletions. Our aim was to assess volumes and averaged annual growth-rates of CNF and PNF in patients with NF1 whole gene deletions and to compare these with NF1 patients without large deletions of the NF1 gene. We retrospectively evaluated 140 whole-body MR examinations of 38 patients with NF1 whole gene deletions (type-1 group: n = 27/atypical group n = 11) and an age- and sex matched collective of 38 NF1-patients. Age-dependent subgroups were created (0-18 vs >18 years). Sixty-four patients received follow-up MRI examinations (NF1whole gene deletion n = 32/control group n = 32). Whole-body tumor-volumes were semi-automatically assessed (MedX, V3.42). Tumor volumes and averaged annual growth-rates were compared. Median tumor-burden was significantly higher in the type-1 group (418ml; IQR 77 - 950ml, p = 0.012) but not in the atypical group (356ml;IQR 140-1190ml, p = 0.099) when compared to the controls (49ml; IQR 11-691ml). Averaged annual growth rates were significantly higher in both the type-1 group (14%/year; IQR 45-36%/year, p = 0.004) and atypical group (11%/year; IQR 5-23%/year, p = 0.014) compared to the controls (4%/year; IQR1-8%/year). Averaged annual growth rates were significantly higher in pediatric patients with type-1 deletions (21%/year) compared with adult patients (8%/year, p = 0.014) and also compared with pediatric patients without large deletions of the NF1 gene (3.3%/year, p = 0.0015). NF1 whole gene deletions cause a more severe phenotype of NF1 with higher tumor burden and higher growth-rates compared to NF1 patients without large deletions of the NF1 gene. In particular, pediatric patients with type-1 deletions display a pronounced tumor growth.

Identifiants

pubmed: 33951044
doi: 10.1371/journal.pgen.1009517
pii: PGENETICS-D-20-01921
pmc: PMC8099117
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1009517

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Hum Genet. 2017 Apr;136(4):349-376
pubmed: 28213670
Genes Chromosomes Cancer. 2012 May;51(5):447-51
pubmed: 22294457
J Clin Oncol. 2016 Jun 10;34(17):1978-86
pubmed: 26926675
J Med Genet. 1998 Jun;35(6):468-71
pubmed: 9643287
Cancer Cell. 2008 Feb;13(2):117-28
pubmed: 18242512
Cancer. 1986 May 15;57(10):2006-21
pubmed: 3082508
Hum Mutat. 2010 Jun;31(6):E1506-18
pubmed: 20513137
Hum Mol Genet. 2000 Jan 1;9(1):35-46
pubmed: 10587576
Hum Mutat. 2011 Feb;32(2):213-9
pubmed: 21280148
Anticancer Res. 2003 Mar-Apr;23(2A):949-52
pubmed: 12820328
Clin Genet. 2013 Oct;84(4):344-9
pubmed: 23278345
Sci Rep. 2015 Jun 09;5:11291
pubmed: 26056819
J Med Genet. 2009 Feb;46(2):81-5
pubmed: 18930997
J Med Genet. 2010 Sep;47(9):623-30
pubmed: 20543202
Hum Mutat. 2004 Feb;23(2):111-6
pubmed: 14722914
J Med Genet. 1989 Nov;26(11):712-21
pubmed: 2511319
PLoS One. 2012;7(4):e35711
pubmed: 22558206
Anticancer Res. 2007 Jul-Aug;27(4A):1819-22
pubmed: 17649778
Orphanet J Rare Dis. 2012 Oct 04;7:75
pubmed: 23035791
Am J Hum Genet. 2001 Sep;69(3):516-27
pubmed: 11468690
Arch Dermatol. 2005 Jan;141(1):71-4
pubmed: 15655144
J Neurooncol. 2014 Jan;116(2):307-13
pubmed: 24166582
N Engl J Med. 2020 Apr 9;382(15):1430-1442
pubmed: 32187457
Am J Hum Genet. 2003 May;72(5):1288-92
pubmed: 12660952
Hum Mutat. 1997;9(5):458-64
pubmed: 9143927
Neuro Oncol. 2008 Aug;10(4):593-8
pubmed: 18559970
Neurology. 2007 Feb 27;68(9):643-7
pubmed: 17215493
Hum Mutat. 2020 Jul;41(7):1226-1231
pubmed: 32248581
J Child Neurol. 2002 Aug;17(8):573-7; discussion 602-4, 646-51
pubmed: 12403555
Radiology. 2009 Mar;250(3):665-73
pubmed: 19244040
Neurology. 2005 Jul 26;65(2):205-11
pubmed: 16043787
J Med Genet. 2004 Jan;41(1):35-41
pubmed: 14729829
Neuro Oncol. 2020 Sep 29;22(9):1368-1378
pubmed: 32152628
Rofo. 2015 Dec;187(12):1084-92
pubmed: 26333104
Hum Genet. 2019 Jan;138(1):73-81
pubmed: 30478644
J Child Neurol. 2002 Aug;17(8):562-70; discussion 571-2, 646-51
pubmed: 12403554
J Med Genet. 2002 May;39(5):311-4
pubmed: 12011145
Hum Mutat. 2003 Nov;22(5):420
pubmed: 14517963
Comput Med Imaging Graph. 2004 Jul;28(5):257-65
pubmed: 15249071
Hum Mol Genet. 2001 Jun 15;10(13):1387-92
pubmed: 11440991
Neurofibromatosis. 1988;1(3):172-8
pubmed: 3152465
Am J Med Genet A. 2015 Jul;167(7):1518-24
pubmed: 25900062

Auteurs

Lennart Well (L)

Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Kimberly Döbel (K)

Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Lan Kluwe (L)

Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Department of Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Peter Bannas (P)

Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Said Farschtschi (S)

Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Gerhard Adam (G)

Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Victor-Felix Mautner (VF)

Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Johannes Salamon (J)

Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH